Phenotypes Associated with This Genotype

Genotype
MGI:5316652

cx4

• Allelic Composition: Col1a1^{tm1(tetO-YAP1*)Fcam}/Col1a1⁺; Tg(Cebpb-tTA)#Bjd/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

liver/biliary system

decreased hepatocyte apoptosis ( J:141457 )

• resistance to Fas-mediated apoptosis after doxycycline withdrawal

increased hepatocyte proliferation ( J:141457 )

• after doxycycline withdrawal

enlarged liver ( J:141457 )

• 4-fold after doxycycline withdrawal for 35 days

• however, increased liver size is reversible by treatment with doxycycline

increased liver weight ( J:141457 )

• after doxycycline withdrawal

• however, increased liver weight is reversible by treatment with doxycycline

liver hyperplasia ( J:141457 )

• after doxycycline withdrawal

abnormal hepatocyte morphology ( J:141457 )

• dysplastic hepatocytes with irregular, enlarged nuclei and a high to nuclear to cytoplasmic ratio after doxycycline withdrawal

cellular

decreased hepatocyte apoptosis ( J:141457 )

• resistance to Fas-mediated apoptosis after doxycycline withdrawal

increased hepatocyte proliferation ( J:141457 )

• after doxycycline withdrawal

growth/size/body

enlarged liver ( J:141457 )

• 4-fold after doxycycline withdrawal for 35 days

• however, increased liver size is reversible by treatment with doxycycline

increased liver weight ( J:141457 )

• after doxycycline withdrawal

• however, increased liver weight is reversible by treatment with doxycycline

liver hyperplasia ( J:141457 )

• after doxycycline withdrawal